Akero Therapeutics, Inc

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis	MASH With Fibrosis; NASH With Fibrosis	Recruiting	Phase 3	2026-10-06	NCT06215716
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH	Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease	Recruiting	Phase 3	2026-09-21	NCT06528314
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease	Active, not recruiting	Phase 3	2026-04-30	NCT06161571

Clinical trials